Fibplant

Company Overview

Snapshot

Founded in May 2019 by Haim Eliyahu, Fibplant operates with 1–10 employees. The company has secured funding across two rounds, with its initial grant received in May 2019.

Business overview

Fibplant is a Health Tech & Life Sciences company focused on developing genetically engineered fibrinogen for use as a biological glue within the existing pharmaceutical drug market. The company's core technology involves advanced active compositions based on therapeutic proteins produced in transgenic plants, targeting applications in surgery and emergency medicine. Fibplant operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, and serves the Life Sciences and Pharmaceutical industries across North America, Europe, and Southeast Asia.

Company Intelligence Q&A

What is Fibplant's primary focus?

Fibplant is developing a genetically engineered fibrinogen, intended for use as a biological glue in the pharmaceutical drug market, particularly for surgery and emergency medicine applications.

When was Fibplant founded?

Fibplant was founded in May 2019.

Who are the founders of Fibplant?

Haim Eliyahu is a founder of Fibplant.

What is Fibplant's product development stage?

Fibplant's product is currently in the R&D stage, focusing on advanced active compositions based on therapeutic proteins produced in transgenic plants.

Which markets does Fibplant target?

Fibplant targets geomarkets including North America, Europe, and Southeast Asia.